NeutriSci International Inc
NeutriSci International Inc. develops and markets nutraceutical products in Canada, Germany, and Japan. It offers neuenergy, an energy tab designed to deliver enhanced focus and mental clarity. The company sells its products through a distribution network of retail storefront and online markets. NeutriSci International Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
NeutriSci International Inc (NRXCF) - Net Assets
Latest net assets as of September 2023: $-914.77K USD
Based on the latest financial reports, NeutriSci International Inc (NRXCF) has net assets worth $-914.77K USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($127.83K) and total liabilities ($1.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-914.77K |
| % of Total Assets | -715.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | -323.71% |
| 10-Year Change | -123.19% |
| Growth Volatility | 238.99 |
NeutriSci International Inc - Net Assets Trend (2001–2022)
This chart illustrates how NeutriSci International Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NeutriSci International Inc (2001–2022)
The table below shows the annual net assets of NeutriSci International Inc from 2001 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-616.97K | -1196.16% |
| 2021-12-31 | $-47.60K | +47.25% |
| 2020-12-31 | $-90.24K | +42.24% |
| 2019-12-31 | $-156.24K | -156.65% |
| 2018-12-31 | $275.79K | +109.91% |
| 2017-12-31 | $131.39K | -80.22% |
| 2016-12-31 | $664.22K | -8.63% |
| 2015-12-31 | $726.98K | -21.72% |
| 2014-12-31 | $928.71K | -65.09% |
| 2014-09-30 | $2.66 Million | +477.05% |
| 2012-12-31 | $-705.48K | +92.26% |
| 2011-12-31 | $-9.12 Million | -37.38% |
| 2010-12-31 | $-6.64 Million | -46.35% |
| 2009-12-31 | $-4.53 Million | -62.41% |
| 2008-12-31 | $-2.79 Million | -222.10% |
| 2007-12-31 | $-866.86K | -1368.13% |
| 2006-12-31 | $-59.05K | +87.90% |
| 2005-12-31 | $-487.78K | -94.86% |
| 2004-12-31 | $-250.32K | -123.53% |
| 2003-12-31 | $1.06 Million | +674.90% |
| 2002-12-31 | $137.29K | -59.33% |
| 2001-12-31 | $337.55K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NeutriSci International Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3644718100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $31.03 Million | % |
| Other Comprehensive Income | $239.51K | % |
| Other Components | $4.58 Million | % |
| Total Equity | $-616.97K | 100.00% |
NeutriSci International Inc Competitors by Market Cap
The table below lists competitors of NeutriSci International Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wealth Invest Baron Glob Akt
CO:WEIBGA
|
$231.88K |
|
ACEA (DCA.SG)
STU:DCA
|
$231.96K |
|
Argo Group US Inc. 6.5% SR NTS 42
NYSE:ARGD
|
$232.01K |
|
KMRSF
PINK:KMRSF
|
$232.07K |
|
DI Corp.
KQ:003160
|
$231.74K |
|
MGO Global Inc. Common Stock
NASDAQ:MGOL
|
$231.72K |
|
Lang & Schwarz Aktiengesellschaft
XETRA:LUS1
|
$231.67K |
|
New Mountain Finance Corporation 8.250% Notes due 2028
NASDAQ:NMFCZ
|
$231.59K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NeutriSci International Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -47,600 to -616,973, a change of -569,373.
- Net loss of 770,694 reduced equity.
- New share issuances of 196,774 increased equity.
- Other factors increased equity by 4,547.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-770.69K | -124.92% |
| Share Issuances | $196.77K | +31.89% |
| Other Changes | $4.55K | +0.74% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares NeutriSci International Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $0.00 | $0.00 | x |
| 2002-12-31 | $1.98 | $0.00 | x |
| 2003-12-31 | $2.42 | $0.00 | x |
| 2004-12-31 | $-0.34 | $0.00 | x |
| 2005-12-31 | $-0.37 | $0.00 | x |
| 2006-12-31 | $-0.02 | $0.00 | x |
| 2007-12-31 | $-0.28 | $0.00 | x |
| 2008-12-31 | $-0.87 | $0.00 | x |
| 2009-12-31 | $-1.39 | $0.00 | x |
| 2010-12-31 | $-2.04 | $0.00 | x |
| 2011-12-31 | $-2.80 | $0.00 | x |
| 2012-12-31 | $-0.22 | $0.00 | x |
| 2014-12-31 | $0.12 | $0.00 | x |
| 2015-12-31 | $0.02 | $0.00 | x |
| 2016-12-31 | $0.01 | $0.00 | x |
| 2017-12-31 | $0.00 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NeutriSci International Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -168.37%
- • Asset Turnover: 1.38x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-176.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -4.54% | -342.03% | 0.01x | 1.02x | $-49.08K |
| 2002 | -145.86% | -8393.08% | 0.01x | 1.25x | $-213.99K |
| 2003 | -94.86% | -50638.03% | 0.00x | 1.23x | $-1.12 Million |
| 2004 | 0.00% | -2733.00% | 0.26x | 0.00x | $-2.75 Million |
| 2005 | 0.00% | -3198.82% | 0.17x | 0.00x | $-1.93 Million |
| 2006 | 0.00% | -463.34% | 0.73x | 0.00x | $-1.80 Million |
| 2007 | 0.00% | -482.56% | 2.98x | 0.00x | $-2.96 Million |
| 2008 | 0.00% | -662.43% | 1.70x | 0.00x | $-1.78 Million |
| 2009 | 0.00% | -360.16% | 2.90x | 0.00x | $-1.30 Million |
| 2010 | 0.00% | -982.07% | 2.39x | 0.00x | $-1.48 Million |
| 2011 | 0.00% | -907.23% | 2.15x | 0.00x | $-1.58 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $7.98 Million |
| 2014 | -41.89% | 0.00% | 0.00x | 2.76x | $-481.95K |
| 2015 | -550.97% | -14411.23% | 0.02x | 2.35x | $-4.08 Million |
| 2016 | -386.14% | -2046.12% | 0.11x | 1.72x | $-2.63 Million |
| 2017 | -1615.28% | -1404.81% | 0.25x | 4.58x | $-2.14 Million |
| 2018 | -864.02% | -2882.67% | 0.15x | 2.01x | $-2.41 Million |
| 2019 | 0.00% | -1670.71% | 0.19x | 0.00x | $-1.60 Million |
| 2020 | 0.00% | -2618.34% | 0.14x | 0.00x | $-1.94 Million |
| 2021 | 0.00% | -1943.53% | 0.10x | 0.00x | $-1.57 Million |
| 2022 | 0.00% | -168.37% | 1.38x | 0.00x | $-709.00K |
Industry Comparison
This section compares NeutriSci International Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NeutriSci International Inc (NRXCF) | $-914.77K | -4.54% | N/A | $231.82K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |